98
Participants
Start Date
September 30, 2002
Primary Completion Date
November 30, 2003
Study Completion Date
November 30, 2003
Lurasidone 20 mg
Lurasidone 20mg oral tablet taken once daily for 6-months
Lurasidone 40 mg
Lurasidone 40mg oral tablets taken once daily
Lurasidone 80mg
Lurasidone 80mg oral tablet taken once daily
Quantum Clinical Services Group, Philadelphia
Albert Einstein Medical Center, Philadelphia
Psychiatric Institute of Washington, Washington D.C.
CNS, Inc., Falls Church
Coordinated Research of Florida, Inc, Winter Park
Comprehensive Neuroscience. Inc., Melbourne
Segal Institute for Clinical Research, North Miami
University of South Florida, Tampa
Birmingham Psychiatry Pharmaceutical, Birmingham
Medstream, Inc., Milwaukee
Alexian Brothers Behavioral Health Hospital, Hoffman Estates
American Medical Research, Oak Brook
St. Paul Medical Center, Dallas
Claghorn Lesem Research Clinic, Inc., Bellaire
Community Clinical Research, Austin
FutureSearch Trials, Austin
Lake Mead Hospital, North Las Vegas
Institute for Psychopharmacology Research, Cerritos
California Clinical Trials Medical Group, Glendale
Optimum Health Services, La Mesa
California Neuropsychopharmacology Clinical Research Institute, San Diego
CNS Network, Garden Grove
University of California, Irvine, Orange
Hawaii Research Center, Honolulu
Comprehensive Clinical Research, CNS, Clementon
ClinSearch, Inc., Kenilworth
Sumitomo Pharma America, Inc.
INDUSTRY